Personal information

Emails & domains

Verified email domains

Countries

United States

Activities

Collapse all

Employment (4)

University of Maryland School of Medicine: Baltimore, MD, US

2020-10-01 to present | Assistant Professor (Microbiology and Immunology/CVD)
Employment
Source: Self-asserted source
Lynda Coughlan

The Mount Sinai Hospital: New York, NY, US

2017-02-06 to 2020-09-30 | PI/Assistant Professor (Dept of Microbiology, Icahn School of Medicine)
Employment
Source: Self-asserted source
Lynda Coughlan

University of Oxford: Oxford, Oxfordshire, GB

2012-08-01 to 2016-12-31 | Post-doctoral fellow (Jenner Institute)
Employment
Source: Self-asserted source
Lynda Coughlan

University of Glasgow: Glasgow, Glasgow, GB

2009-08-01 to 2012-07-25 | Post-doctoral research associate (Glasgow Cardiovascular Research Centre)
Employment
Source: Self-asserted source
Lynda Coughlan

Education and qualifications (4)

Barts Cancer Institute: London, London, GB

2005-09-01 to 2009-07-25 | PhD (Tumour Biology and Molecular Oncology)
Education
Source: Self-asserted source
Lynda Coughlan

Institut Català d' Oncologia: L'Hospitalet de Llobregat, Catalunya, ES

2008-03-01 to 2008-09-30 (Oncolytic Viral Therapy)
Education
Source: Self-asserted source
Lynda Coughlan

London School of Hygiene and Tropical Medicine: London, London, GB

2004-09-01 to 2005-08-30 | MSc Virology
Education
Source: Self-asserted source
Lynda Coughlan

University College Cork: Cork, IE

1998-09-01 to 2003-06-01 | BSc Microbiology (Microbiology)
Education
Source: Self-asserted source
Lynda Coughlan

Professional activities (7)

International Society for Extracellular Vesicles: New Jersey, New Jersey, US

Membership
Source: Self-asserted source
Lynda Coughlan

American Society of Gene Therapy and Cell Therapy: Milwaukee, Wisconsin, US

Membership
Source: Self-asserted source
Lynda Coughlan

American Society for Microbiology: Washington D.C., District of Columbia, US

Membership
Source: Self-asserted source
Lynda Coughlan

Pediatric Infectious Diseases Society: Arlington, Virginia, US

2017 to present
Membership
Source: Self-asserted source
Lynda Coughlan

British Society for Immunology: London, GB

2016 to present
Membership
Source: Self-asserted source
Lynda Coughlan

International Society for Influenza and other Respiratory Virus Diseases: Atlanta, Georgia, US

2015 to present
Membership
Source: Self-asserted source
Lynda Coughlan

Microbiology Society: London, London, GB

2005 to present | Member
Membership
Source: Self-asserted source
Lynda Coughlan

Funding (10)

Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine

2022-07-01 to 2026-06-30 | Grant
National Institute of Allergy and Infectious Diseases (Bethesda, US)
URL: https://app.dimensions.ai/details/grant/grant.12916780
GRANT_NUMBER: R01AI148369
Source: Self-asserted source
Lynda Coughlan via DimensionsWizard

Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectors.

2020-07 to 2022-07 | Grant
National Institute of Allergy and Infectious Diseases (Md., Md., US)
GRANT_NUMBER:

R21AI157606
Source: Self-asserted source
Lynda Coughlan

Generation of a polycistronic universal influenza virus vaccine based on rare species adenoviral vectors

2019-08-06 to 2021-07-31 | Grant
National Institute of Allergy and Infectious Diseases (Bethesda, US)
URL: https://app.dimensions.ai/details/grant/grant.8554097
GRANT_NUMBER: R21AI146529
Source: Self-asserted source
Lynda Coughlan via DimensionsWizard

Investigation and exploitation of exosome-display technology to generate a novel pediatric vaccine for Respiratory Syncytial Virus

2018-11 to 2021-10 | Grant
Pediatric Infectious Diseases Society (VA, VA, US)
GRANT_NUMBER:

Pichichero Family Foundation Vaccines for Children Initiative Research Award
Source: Self-asserted source
Lynda Coughlan

Toward a Universal Influenza Virus Vaccine

2018-08 to 2023-08 | Grant
National Institutes of Health (MD, MD, US)
GRANT_NUMBER:

AI097092-06 (Palese)

Source: Self-asserted source
Lynda Coughlan

Development of exosome-display technology to generate novel universal adenoviral vectored influenza vaccines with improved immunogenicity.

2017-08 to 2018-08 | Contract
National Institute of Allergy and Infectious Diseases (MD, MD, US)
Source: Self-asserted source
Lynda Coughlan

Investigation and exploitation of exosomes in the development of novel influenza vaccines with improved immunogenicity

2017-07 to 2018-07 | Grant
Sigma Delta Epsilon-Graduate Women in Science (MN, MN, US)
GRANT_NUMBER: Nell Mondy and Monique Braude Fellowship
Source: Self-asserted source
Lynda Coughlan

Investigation and exploitation of exosomes in the development of novel influenza vaccines with improved immunogenicity

2016-09 to 2019-08 | Grant
British Medical Association (London, GB)
GRANT_NUMBER: HC Roscoe Grant 2016
Source: Self-asserted source
Lynda Coughlan

Investigation and exploitation of exosomes to improve vaccines for emerging viral infections

2016-08 to 2017-08 | Grant
Royal Society of Tropical Medicine and Hygiene (London, GB)
GRANT_NUMBER: GR000550
Source: Self-asserted source
Lynda Coughlan

Improving the immunogenicity of antigens expressed by viral vectored vaccines for infectious disease by use of exosome-display technology

2015-06 to 2016-12 | Grant
University of Oxford (Oxford, GB)
GRANT_NUMBER: MRF/TT2015/2150
Source: Self-asserted source
Lynda Coughlan

Works (50 of 56)

Items per page:
Page 1 of 2

An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases

mBio
2025-02-05 | Journal article
DOI: 10.1128/mbio.03387-24
Contributors: Kari Ann Shirey; John Joseph; Lynda Coughlan; Haye Nijhuis; Alan W. Varley; Jorge C. G. Blanco; Stefanie N. Vogel; Sara Cherry
Source: check_circle
Crossref

Muscle macrophage regenerative response after squalene-adjuvanted influenza vaccination drives Th2-skewed response and is reduced with age

2025-01-28 | Preprint
DOI: 10.21203/rs.3.rs-5760877/v1
Contributors: Moataz Noureddine; Lauren Chang; Farah El-Ayache; Gabriel Laghlali; Eleanor Burgess; Leonie Grueneberg; Prajakta Warang; Kaijun Jiang; Haye Nijhuis; Lynda Coughlan et al.
Source: check_circle
Crossref

Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.

Vaccine
2025-01-04 | Journal article
DOI: 10.1016/j.vaccine.2024.126689
PMID: 39756216
Contributors: El Sahly HM; Anderson EJ; Jackson LA; Neuzil KM; Atmar RL; Bernstein DI; Chen WH; Creech CB; Frey SE; Goepfert P et al.
Source: Self-asserted source
Lynda Coughlan

A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.

EBioMedicine
2024-05-27 | Journal article
DOI: 10.1016/j.ebiom.2024.105153
PMID: 38805853
PMC: PMC11154122
Contributors: Bliss CM; Nachbagauer R; Mariottini C; Cuevas F; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F et al.
Source: Self-asserted source
Lynda Coughlan

Outpacing antiviral resistance: new treatments for influenza virus infection.

The Lancet. Infectious diseases
2024-02-05 | Journal article
DOI: 10.1016/s1473-3099(23)00820-4
PMID: 38330976
Contributors: Coughlan L; Neuzil KM
Source: Self-asserted source
Lynda Coughlan

Viral platform engineering for targeted gene delivery to human hematopoietic stem cells

Molecular Therapy
2024-01 | Journal article
DOI: 10.1016/j.ymthe.2023.11.025
Contributors: Samanta Del Veliz; Lynda Coughlan
Source: check_circle
Crossref

Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.

Science advances
2023-09-13 | Journal article | Author
DOI: 10.1126/sciadv.adi4753
PMID: 37703367
PMC: PMC10499326
Contributors: Eduard Puente-Massaguer; Kirill Vasilev; Annika; Madhumathi Loganathan; Benjamin Francis; Michael Scherm; Guha Asthagiri Arunkumar; Irene González-Domínguez; Xueyong Zhu; Ian Wilson et al.
Source: Self-asserted source
Lynda Coughlan

Always a bridesmaid, never a bride: Committing to flu neuraminidase as a vaccine target

Molecular Therapy
2023-07 | Journal article
DOI: 10.1016/j.ymthe.2023.04.014
Contributors: Cosette Schneider; Lynda Coughlan
Source: check_circle
Crossref

Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination

Journal of Virology
2023-03-30 | Journal article
DOI: 10.1128/jvi.01664-22
Contributors: Fatima Amanat; Jordan Clark; Juan Manuel Carreño; Shirin Strohmeier; Temima Yellin; Philip S. Meade; Disha Bhavsar; Hiromi Muramatsu; Weina Sun; Lynda Coughlan et al.
Source: check_circle
Crossref

Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice.

Scientific reports
2023-01-13 | Journal article
DOI: 10.1038/s41598-023-27965-x
PMID: 36639569
PMC: PMC9838488
Contributors: Haupt R; Baracco L; Harberts EM; Loganathan M; Kerstetter LJ; Krammer F; Coughlan L; Ernst RK; Frieman MB
Source: Self-asserted source
Lynda Coughlan

RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine.

Frontiers in immunology
2022-11-08 | Journal article
DOI: 10.3389/fimmu.2022.974016
PMID: 36426358
PMC: PMC9679288
Contributors: Jangra S; Laghlali G; Choi A; Rathnasinghe R; Chen Y; Yildiz S; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M
Source: Self-asserted source
Lynda Coughlan

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

npj Vaccines
2022-08-30 | Journal article
DOI: 10.1038/s41541-022-00524-7
Contributors: Johannes B. Goll; Aarti Jain; Travis L. Jensen; Rafael Assis; Rie Nakajima; Algis Jasinskas; Lynda Coughlan; Sami R. Cherikh; Casey E. Gelber; S. Khan et al.
Source: check_circle
Crossref

Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.

Microbiology spectrum
2022-06 | Journal article
DOI: 10.1128/spectrum.01538-22
PMID: 35658571
Contributors: González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M et al.
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.

Molecular therapy : the journal of the American Society of Gene Therapy
2022-01 | Journal article
DOI: 10.1016/j.ymthe.2022.01.011
PMID: 34999208
Contributors: Bliss CM; Freyn AW; Caniels TG; Leyva-Grado VH; Nachbagauer R; Sun W; Tan GS; Gillespie VL; McMahon M; Krammer F et al.
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.

Molecular therapy : the journal of the American Society of Gene Therapy
2022-01 | Journal article
DOI: 10.1016/j.ymthe.2022.01.034
PMID: 35092844
PMC: PMC8801892
Contributors: Coughlan L; Kremer EJ; Shayakhmetov DM
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Caught in a trap: How pre-clinical studies in laboratory mice exaggerate vaccine responses.

Cell reports. Medicine
2021-12 | Journal article
DOI: 10.1016/j.xcrm.2021.100484
PMID: 35028623
PMC: PMC8715072
Contributors: Coughlan L
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Broadly neutralizing antibodies target a hemagglutinin anchor epitope.

Nature
2021-12-23 | Journal article
DOI: 10.1038/s41586-021-04356-8
PMID: 34942633
Source: Self-asserted source
Lynda Coughlan
grade
Preferred source (of 2)‎

Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus

PLOS Biology
2021-12-16 | Journal article
DOI: 10.1371/journal.pbio.3001384
Contributors: Fatima Amanat; Sarah L. Rowland-Jones; Shirin Strohmeier; Philip S. Meade; Nicholas Dambrauskas; Barbara Mühlemann; Derek J. Smith; Vladimir Vigdorovich; D. Noah Sather; Lynda Coughlan et al.
Source: check_circle
Crossref

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.

Science advances
2021-12-01 | Journal article
DOI: 10.1126/sciadv.abl8213
PMID: 34851659
Source: Self-asserted source
Lynda Coughlan

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Nature Communications
2021-10-27 | Journal article
DOI: 10.1038/s41467-021-26499-y
Contributors: Weina Sun; Yonghong Liu; Fatima Amanat; Irene González-Domínguez; Stephen McCroskery; Stefan Slamanig; Lynda Coughlan; Victoria Rosado; Nicholas Lemus; Sonia Jangra et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.

Nature communications
2021-10-20 | Journal article
DOI: 10.1038/s41467-021-26354-0
PMID: 34671037
PMC: PMC8528857
Source: Self-asserted source
Lynda Coughlan

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner.

mBio
2021-07-27 | Journal article
DOI: 10.1128/mbio.01002-21
PMID: 34311574
PMC: PMC8406178
Source: Self-asserted source
Lynda Coughlan

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

mBio
2021-04-27 | Journal article
DOI: 10.1128/mBio.02648-20
Contributors: Fatima Amanat; Shirin Strohmeier; Raveen Rathnasinghe; Michael Schotsaert; Lynda Coughlan; Adolfo García-Sastre; Florian Krammer; Vincent R. Racaniello
Source: check_circle
Crossref

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

Science (New York, N.Y.)
2021-01 | Journal article
DOI: 10.1126/science.abf4058
PMID: 33495306
Contributors: White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L et al.
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central
grade
Preferred source (of 2)‎

Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.

Frontiers in immunology
2021-01-29 | Journal article
DOI: 10.3389/fimmu.2020.607333
PMID: 33633727
Source: Self-asserted source
Lynda Coughlan

Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.

Angewandte Chemie (International ed. in English)
2021-01-19 | Journal article
DOI: 10.1002/anie.202015362
PMID: 33464672
Source: Self-asserted source
Lynda Coughlan

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

Nature medicine
2020-12-07 | Journal article
DOI: 10.1038/s41591-020-1118-7
PMID: 33288923
Source: Self-asserted source
Lynda Coughlan

Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.

Science translational medicine
2020-12-01 | Journal article
DOI: 10.1126/scitranslmed.abd3601
PMID: 33298562
Source: Self-asserted source
Lynda Coughlan

Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies

Vaccines
2020-11-09 | Journal article
DOI: 10.3390/vaccines8040666
Contributors: Juan Manuel Carreño; Jacqueline U. McDonald; Tara Hurst; Peter Rigsby; Eleanor Atkinson; Lethia Charles; Raffael Nachbagauer; Mohammad Amin Behzadi; Shirin Strohmeier; Lynda Coughlan et al.
Source: check_circle
Crossref

Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses.

Immunity
2020-10 | Journal article
DOI: 10.1016/j.immuni.2020.10.005
PMID: 33096040
Contributors: Guthmiller JJ; Lan LY; Fernández-Quintero ML; Han J; Utset HA; Bitar DJ; Hamel NJ; Stovicek O; Li L; Tepora M et al.
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central
grade
Preferred source (of 2)‎

Snatching the Crown from SARS-CoV-2

Cell Host & Microbe
2020-09 | Journal article
DOI: 10.1016/j.chom.2020.08.007
Contributors: Lynda Coughlan
Source: check_circle
Crossref

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.

Frontiers in immunology
2020-05-19 | Journal article
DOI: 10.3389/fimmu.2020.00909
PMID: 32508823
PMC: PMC7248264
Source: Self-asserted source
Lynda Coughlan

A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

Molecular therapy : the journal of the American Society of Gene Therapy
2020-04-19 | Journal article
DOI: 10.1016/j.ymthe.2020.04.018
PMID: 32359470
Source: Self-asserted source
Lynda Coughlan

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection

Emerging Microbes & Infections
2020-01 | Journal article
DOI: 10.1080/22221751.2020.1838955
Contributors: Raveen Rathnasinghe; Shirin Strohmeier; Fatima Amanat; Virginia L. Gillespie; Florian Krammer; Adolfo García-Sastre; Lynda Coughlan; Michael Schotsaert; Melissa B. Uccellini
Source: check_circle
Crossref

Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice.

Molecular therapy. Methods & clinical development
2019-12-24 | Journal article
DOI: 10.1016/j.omtm.2019.12.003
PMID: 31934599
PMC: PMC6953706
Source: Self-asserted source
Lynda Coughlan

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions

Nature Communications
2019-02-14 | Journal article
DOI: 10.1038/s41467-019-08599-y
Contributors: Alexander T. Baker; Alexander Greenshields-Watson; Lynda Coughlan; James A. Davies; Hanni Uusi-Kerttula; David K. Cole; Pierre J. Rizkallah; Alan L. Parker
Source: check_circle
Crossref

Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine

Cell Host and Microbe
2018 | Journal article
DOI: 10.1016/j.chom.2018.06.016
EID:

2-s2.0-85049315230
Contributors: Coughlan, L.; Palese, P.
Source: Self-asserted source
Lynda Coughlan via Scopus - Elsevier

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.

EBioMedicine
2018-03 | Journal article
DOI: 10.1016/j.ebiom.2018.02.011
PMID: 29519670
Contributors: Coughlan L; Sridhar S; Payne R; Edmans M; Milicic A; Venkatraman N; Lugonja B; Clifton L; Qi C; Folegatti PM et al.
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.

Molecular cancer therapeutics
2018-02 | Journal article
DOI: 10.1158/1535-7163.mct-17-0671
PMID: 29367266
Contributors: Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central
grade
Preferred source (of 2)‎

Defining a novel role for the coxsackie and adenovirus receptor in human adenovirus serotype 5 transduction in vitro in the presence of mouse serum.

Journal of Virology
2017-04 | Journal article
DOI: 10.1128/jvi.02487-16
PMID: 28381574
Source: Self-asserted source
Lynda Coughlan
grade
Preferred source (of 3)‎

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

2016-05 | Journal article
DOI: 10.18632/oncotarget.8545
PMID: 27056886
Contributors: Uusi-Kerttula H; Davies J; Coughlan L; Hulin-Curtis S; Jones R; Hanna L; Chester JD; Parker AL
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.

2015 | Journal article
DOI: 10.1038/srep16756
PMID: 26576856
PMC: PMC4649739
Contributors: Dicks MD; Spencer AJ; Coughlan L; Bauza K; Gilbert SC; Hill AV; Cottingham MG
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges

Vaccines
2015 | Journal article
DOI: 10.3390/vaccines3020293
PMID: 26343189
PMC: PMCID: PMC4494351
EID:

2-s2.0-85016872290

Part of ISSN: 2076393X
Source: Self-asserted source
Lynda Coughlan
grade
Preferred source (of 2)‎

Adenoviral vectors as novel vaccines for influenza.

2015-03 | Journal article
DOI: 10.1111/jphp.12350
PMID: 25560474
Contributors: Coughlan L; Mullarkey C; Gilbert S
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Genetically engineering adenoviral vectors for gene therapy.

2014 | Journal article
DOI: 10.1007/978-1-62703-751-8_2
PMID: 24243238
Contributors: Coughlan L
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

2014-04 | Journal article
DOI: 10.1089/hum.2014.016
PMID: 24617540
Contributors: Coughlan L; Uusi-Kerttula H; Ma J; Degg BP; Parker AL; Baker AH
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

2014-03 | Journal article
DOI: 10.1038/mt.2013.284
PMID: 24374965
PMC: PMC3944330
Contributors: Antrobus RD; Coughlan L; Berthoud TK; Dicks MD; Hill AV; Lambe T; Gilbert SC
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

2014-01 | Journal article
DOI: 10.1038/mt.2013.162
PMID: 23831594
PMC: PMC3978791
Contributors: Antrobus RD; Berthoud TK; Mullarkey CE; Hoschler K; Coughlan L; Zambon M; Hill AV; Gilbert SC
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery.

2012-12 | Journal article
DOI: 10.1038/mt.2012.162
PMID: 22929662
PMC: PMC3514487
Contributors: Coughlan L; Bradshaw AC; Parker AL; Robinson H; White K; Custers J; Goudsmit J; Van Roijen N; Barouch DH; Nicklin SA et al.
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central

Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.

2012-12 | Journal article
DOI: 10.1016/j.jconrel.2012.05.025
PMID: 22626939
PMC: PMC3520007
Contributors: Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH
Source: Self-asserted source
Lynda Coughlan via Europe PubMed Central
Items per page:
Page 1 of 2

Peer review (4 reviews for 3 publications/grants)

Review activity for Nature microbiology. (1)
Review activity for PloS one. (1)
Review activity for PLOS pathogens : (2)
How many people are using ORCID?